Evaluating human induced pluripotent stem cell-derived cardiomyocytes for commercial drug testingTools Katili, Puspita Anggraini (2020) Evaluating human induced pluripotent stem cell-derived cardiomyocytes for commercial drug testing. PhD thesis, University of Nottingham.
AbstractThe cost of developing new drugs has increased by ~100 fold in recent decades, largely due to high attrition rate in clinical development caused by cardiotoxicity. Since the recent discovery of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs), it has been developed as a novel, promising in vitro research tool in preclinical testing of drug-induced cardiotoxicity. However, major limitation of currently available hiPSC-CMs is their immature phenotype, which can hinder evaluation of contractile dysfunction.
Actions (Archive Staff Only)
|